Idiopathic Parkinson’s disease and Schizophrenia: Dilemma in diagnosis and treatment
The relationship between schizophrenia and idiopathic Parkinson’s disease is still not clear and rare when they coexist. Diagnosing coexisting schizophrenia and idiopathic Parkinson’s disease is a chal-lenge, especially in developing countries due to lack of experts and advance imaging facilities. Treatment options are also limited. A 58- year- old male was admitted due to relapse of psychotic symptoms following non-compliance to antipsychotic medications. The patient was previously diag-nosed with schizophrenia and later developed Parkinson’s disease while non-compliant to antipsy-chotic medications. While the patient was at our center, his detailed history was taken and general physical examination was done to distinguish Parkinson’s disease from anti-psychotic induced ex-trapyramidal symptoms. All the routine investigations were within normal limits. This case report highlights the clinical factors that help make a distinction and help use appropriate drugs to manage schizophrenia with comorbid Parkinson’s disease in developing countries, where lack of precise di-agnostic imaging modalities interferes in making a conclusive diagnosis.
Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: The path to discovery. Dialogues Clin Neurosci. 2006;8(1):137–42.
Dauer W, Przedborski S. Parkinson’s disease: Mechanisms and models. Vol. 39, Neuron. 2003. p. 889–909.
Grover S, Sahoo S, Goyal M. Schizophrenia with comorbid idiopathic parkinson’s disease: A difficult clinical management scenario. Indian J Psychol Med. 2017;39(6).
de Jong MH, Zemel D, Van Gool AR. Clinical aspects of comorbid schizophrenia and idio-pathic Parkinson’s disease. Clin Schizophr Relat Psychoses [Internet]. 2014;8(1):36–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23428786
Winter C, Juckel G, Plotkin M, Niehaus L, Kupsch A. Paranoid schizophrenia and idiopathic Parkinson’s disease do coexist: A challenge for clinicians . Vol. 60, Psychiatry and Clinical Neurosciences. 2006. p. 639.
Gadit A. Schizophrenia and Parkinson’s disease: Challenges in management. BMJ Case Rep. 2011;
Lam RW. Chronic schizophrenia and idiopathic Parkinson’s disease. Can J Psychiatry. 1993;38(2):75–7.
Plotkin M, Amthauer H, Klaffke S, Kühn A, Lüdemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients *. J Neural Transm. 2005;112(5):677–92.
Friedman JH. Managing idiopathic Parkinson’s disease in patients with schizophrenic disor-ders. Parkinsonism Relat Disord [Internet]. 2011;17(3):198–200. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1353802010002993
Lan CC, Su TP, Chen YS, Bai YM. Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson’s disease. Gen Hosp Psychiatry. 2011;33(4).
Menza MMA, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson’s disease. Ann Clin Psychiatry. 1999;11(3):141–4.
Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clin Neuropharmacol [Internet]. 1997;20(3):204–9. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=1997-04724-001%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9197942
Fernández-Corcuera P, Aguilar S, Viçens V, Mora J, Benitez A, García-Burillo A, et al. ECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualisation using 123I-Ioflupane SPET. J Neural Transm. 2011;118(4):647–50.
Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a seroto-nin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuro-psychopharmacology [Internet]. 2010;35(4):881–92. Available from: http://www.nature.com/npp/journal/v35/n4/full/npp2009176a.html#References
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.